Dr. Ben-Zion Katz

Original articles and reviews:

1. Ran,  M., Tellaud, J.-L., Fridman, W. H., Frenkel, H., Halachmi, E., Katz,  B.-Z., Gips, M., Shlomo, Y., Barzilay, J. and Witz, I. P. Increased expression of Fc receptor in cancer patients and tumor bearing mice. (1988)  Mol. Immunol.  25:1159-1165.

2. Ran, M., Katz, B.-Z., Kimchi, N., Halachmi, E., Tellaud, J.-L., Even, J.,  Berko-Flint, J., Atlas, E., Fridman, W. H. and Witz, I. P. The in-vivo acquisition of FcRII expression on polyoma virus transformed cells derived from tumors of long latency. (1991) Cancer Res. 51:612-618.

3. Ben-Baruch, L. A., Emmanuel, N., Even, J., Fridman, W. H., Gohar, O.,  Gonen, B., Katz, B.-Z., Ran, M., Smorodinsky, N. I. and Witz, I. P. Phenotypic properties of 3T3 cells transformed in-vitro with polyoma virus and passaged once in syngeneic animals. (1992) Immunobiol. 185:415-425.

4. Katz, B.-Z. and Witz, I. P. In-vitro exposure of polyoma virus transformed cells to laminin augments their in-vivo malignancy phenotype. (1993) Invasion Metastasis 13:185-194.

5. Katz, B.-Z., Eshel, R., Sagi-Assif, O. and Witz, I. P. An association between a high Ly-6 expression on tumor cells and a high malignancy phenotype. (1994)  Int. J. Cancer 59:684-691.

6. Katz, B.-Z., Ishai-Michaeli, R., Zusman, T., Vlodavsky, I. and Witz, I. P.  Lung colonization and heparanase activity in in-vitro transformed cells rendered highly tumorigenic by in-vivo passage. (1994) Invasion Metastasis 14:276-289.

7. Eshel, R., Firon, M., Katz, B.-Z., Sagi-Assif, O., Aviram, H. and Witz, I. P.  Microenvironmental factors regulate Ly-6 A/E expression on PyV-transformed BALB/c 3T3 cells. (1995) Immunol. Lett. 44:209-212.

8. Sagi-Assif, O., Traister, A., Katz, B.-Z., Anavi, R., Eskenasy, M. and Witz, I.  P. TNF alpha and anti-Fas antibodies regulate Ly-6E.1 expression by tumor cells:  a possible link between angiogenesis and Ly-6E. (1996) Immunol. Lett.  54:207-13.

9. Katz,  B.-Z. and Yamada, K. M. Integrins in morphogenesis and signaling.  (1997) Biochimie 79:467-476.

10. Levenberg, S, Katz, B.-Z., Yamada, K. M. and Geiger, B. Long-range and selective autoregulation of cell-cell or cell-matrix adhesions by cadherin or integrin ligands. (1998) J. Cell Sci. 111:347-357.

11. Miyamoto, S., Lafrenie, R., Katz, B.-Z. and Yamada, K. M. Fibronectin and integrins in cell adhesion,  signaling and morphogenesis. (1998) Ann. NY Acad.  Sci. 857:119-129.

12. Treister, A., Sagi-Assif, O., Meer, M., Smorodinsky, N. I., Anavi, R., Golan, I., Meshel, T., Kahana, O., Eshel, R., Katz, B.-Z., Shevach, E. and Witz, I. P.  Expression of Ly-6, a marker for high malignant murine tumor cells, is regulated by growth conditions and stress. (1998) Int. J. Cancer 77:306-313.

13. Katz, B.-Z., Krylov, D., Aota, S.-I., Olive, M., Vinson, C. and Yamada, K.  M. Green fluorescent protein labeling of cytoskeletal structures - A novel targeting approach based on leucine zippers. (1998) BioTechniques 25:298-302.
14. Katz, B.-Z., Levenberg, S., Yamada, K. M. and Geiger, B. Modulation of cell-cell adherence junctions by surface clustering of the N-cadherin cytoplasmic tail.(1998) Exp. Cell Res. 243:415-424.
15. Zohar, M., Teramoto, H., Katz, B.-Z., Yamada, K. M. and Gutkind, J. S.  Effector domain mutants of Rho dissociate cytoskeletal changes from nuclear signaling and cellular transformation. (1998) Oncogene 17:991-998.
16. De Nichilo, M., Katz, B.-Z., O'Connell, B. and Yamada, K. M. De novo expression of pp125FAK in human macrophages regulates CSK distribution and MAP kinase activation but does not affect focal contact structure. (1998) J. Cell Physiol. 178:164-172.
17. Zamir, E., Katz, B.-Z., Yamada, K. M., Geiger, B. and Kam, Z. Molecular diversity of cell-matrix adhesions. (1999) J. Cell Sci. 112:1655-1669.
18. Igishi, T., Fukuhara, S., Patel, V., Katz, B.-Z., Yamada, K. M. and Gutkind, J. S. Divergent signaling pathways link FAK to MAP kinase cascades: evidence for a role of paxillin in JNK activation. (1999) J. Biol. Chem. 274:30738-30746.

19. Katz, B.-Z., Zamir, E., Bershadsky, A., Kam, Z., Yamada, K. M. and Geiger,  B. Physical state of the extracellular matrix regulates the structure and molecular composition of cell-matrix adhesions. (1999) Mol. Biol. Cell. 11:1047-1060.
20. Zamir, E., Katz, M., Posan, Y., Erez, N., Yamada, K. M., Katz, B.-Z., Lin, S., Lin, C. D., Bershadsky, A., Kam, Z. and Geiger, B. Dynamics and segregation of cell-matrix adhesions in cultured fibroblasts. (2000) Nature Cell Biol. 2:191-196.

21. Pankov, R., Cukierman, E., Katz, B.-Z., Matsumoto, K., Hahn, K. and Yamada, K. M. Integrin dynamics and matrix assembly: tensin-dependent translocation of 51 integrins promotes early fibronectin fibrillogenesis. (2000) J. Cell Biol. 148:1075-1090.

22. Katz, B.-Z., Zohar, M., Teramoto, H., Matsumoto, K., Gutkind, J. S., Lin, D., Lin, S. and Yamada, K. M. Tensin associates with fibronectin-induced complexes and triggers JNK and p38 activation. (2000) Biochm. Biophys. Res. Commun. 272:717-720.
23. Nadav, L. and Katz B.-Z. The molecular effects of oncogenesis on cell-extracellular matrix adhesion. (2001) Int. J. Oncol. 19: 237-246.
24. Even-Ram, S., Maoz, M., Pokroy, E., Reich, R., Katz, B.-Z., Gutwein, P., Altevogt, P. and Bar-Shavit, R. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with V5 integrin. (2001) J. Biol. Chem. 276:10952-10962.
25. Nadav, L., Geiger, B. and Katz, B.-Z. Heparinoids: integrated control of hemostasis and metastasis. (2002) Isr. Med. Ass. J. 4:1046-1049.
26. Bitan, M., Deutsch, V., Friedmann, Y., Pecker, I., Nadav, L., Polliack, A., Nagler, A., Eldor, A., Vlodavsky, I. and Katz B.-Z. Heparanase expression in leukemias is restricted to AML (2002) Exp. Hematol. 30:34-41.
27. Nadav, L., Yacoby-Zeevi, O., Zamir, E., Pecker, I., Ilan, N., Geiger, B., Eldor, A., Vlodavsky, I. and Katz, B.-Z. Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. (2002) J. Cell Sci. 115:2179-2187.

28. Katz,  B.-Z.,  Miyamoto,  S.,  Teramoto,  H.,  Zohar, M., Krylov, D. V., Vinson, C., Gutkind, J. S. and Yamada,  K. M. Direct Transmembrane Clustering and Cytoplasmic Dimerization of Focal Adhesion Kinase Initiates Its Tyrosine Phosphorylation. (2002) Biochem. Biophys. Acta. 1592:141-152.

29. Goldschmidt, O., Nadav, L., Zamir, E., Geiger, B., Yacoby-Zeevi, O., Vlodavsky, I. and Katz B.-Z. Human heparanase is localizes in lysosomes in a stable manner. (2002) Exp. Cell Res. 281:50-62.
30. Goldshmidt, O., Zcharia, E., Cohen, M., Aingorn, H., Nadav, L., Cohen, I., Katz, B.-Z., Geiger, B. and Vlodavsky, I. Heparanase mediates cell adhesion independent of its endoglycosidase activity. (2003) FASEB J. 17:1015-1025.
 31. Katz, B.-Z., Romer, L., Miyamoto, S., Volberg, T., Matsumoto, K., Geiger, B. and Yamada, K. M. Targeting Membrane-Localized FAK to Focal Adhesions: Roles of Tyrosine Phosphorylation and Src Family Kinases. (2003) J. Biol. Chem. 278:29115-29120.
32. Vlodavsky I., Zcharia E., Goldshmidt O., Eshel R., Katz B.-Z., Minucci S., Kovalchuk O., Penco S., Pisano C., Naggi A., and Casu B. Involvement of heparanase in tumor progression and normal differentiation. (2003) Pathophysiol. Haemost. Thromb. 33 Suppl 1:59-61.

33. Zamir, E., Geiger, B., Cohen, N., Kam Z. and Katz B.-Z. Resolving and Classifying Hematopoietic Bone-Marrow Cell Populations by Multi-Dimensional Analysis of Flow-Cytometry Data. (2005) Br. J. Hematol. 129:420-431.
34. Eshel, R., Ben-Zaken, O., Vainas, O, Nadir, Y., Minucci, S., Polliack, A.,  Naparstek, E., Vlodavsky I. and Katz B.-Z. Leukomogenic factors down regulate heparanase expression by histone deacetylation. (2005) Biochem. Biophys. Res. Commun. 335:1115-1122.
35. Danckwardt, S., Hartmann, K., Katz, B., Hentze, M. W., Levy, Y., Eichele,  Y., Deutsch, V., Kulozik, A. E. and Ben-Tal, O. The prothrombin 20209 CT mutation in Jewish-Moroccan Caucasians: Molecular analysis of gain-of-function of 3’end processing. (2006) J. Thromb. Hemost. 4:1078-1085.
36. Nadav, L.*, Katz, B.-Z.*, Baron, S., Yossipov, L., Deutsch, V., Geiger, B., and Naparstek E. Diverse Niches Within Multiple Myeloma Bone Marrow Samples Affect Plasma Cell Enumeration. (2006) Br. J. Hematol. 133:530-532.* Equal contributors
37. Nadav, L., Katz, B.-Z., Bar-On, S., Cohen, N., Naparstek, E., and Geiger, B. The generation and regulation of functional diversity of malignant plasma cells (2006) Cancer Res. 66:8608-8616.

38. Rubinstein, D. B., Karmely, M., Ziv, R., Benhar, I., Leitner, O., Baron, S., Katz, B.-Z., and Wreschner, D. H. MUC1/X Protein Immunization Enhances cDNA Immunization in Generating Anti-MUC1  /ß Junction Antibodies that Target Malignant Cells (2006) Cancer Res. 66:11247-11253.

39. Vlodavsky, I., Ilan, N., Nadir, Y., Brenner, B., Katz, B.-Z., Naggi, A., Torri, G., Casu, B.,  and Sasisekharan, R. Heparanase, heparin and the coagulation system in cancer progression (2007) Thromb. Res. 120:Suppl 2:S112-120.
40. Katz, B.-Z., Muhl, L., Zwang, E., Ilan, N., Herishanu, Y., Deutsch, V., Naparstek, E., Vlodavsky, I., and Preissner, K.T. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms (2007) Thromb. Haemost. 98:1193-1199.
41. Nadav, L., Kalchenko, V., Barak, M.M., Naparstek, E., Geiger, B. and Katz, B.-Z. The tumorigenic potential and disease manifestations of malignant B-cell variants differing in their fibronectin adhesiveness (2008) Exp. Hematol. 36:1530-1540.
42. Tavor, S., Eisenbach, M., Jacob-Hirsch, J., Kay, S., Baron, S., Katz, B.-Z., petit, I., Amariglio, N., Deutsch V., Naparstek, E., and Rechavi, G. The CXCR4 antagonist AMD3100 impairs survival and induces differentiation of human AML cells (2008) Leukemia 22:5151-5158.
43. Eisenthal, A., Eytan, K., Brazowski, E., Katz, B.-Z., Shirazi, I., and Skornick Y. Effects of 5-fluorouracil on Human Mitogen-activated Peripheral Blood Lymphocytes from Healthy Individuals (2008) Anticancer Res. 28:3785-3791.

44. Salomon, O., Katz, B.-Z., Dardik, R., Livnat T., Steinberg, D.M., Achiron R., and Seligsohn U. Plasma levels of microparticles at 24 weeks of gestation do not predict subsequent pregnancy complications (2009) Fertil. Steril. 92:682-687.
45. Dezorella, N., Pevsner-Fischer, M., Deutsch, V., Baron, S., Stern, R., Tavor, S., Nagler, A., Naparstek, E., Zipori, D., and Katz, B.-Z. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6 (2009) Exp. Cell Res. 315:1904-1913.
46. Helpman, L.*, Katz, B.-Z.*, Safra, T., Schreiber, L., Levine, Z., Nemzer, S., Kinar, Y., and Grisaru, D. Systematic antigenic profiling of ovarian carcinoma cells identifies membrane proteins for targeted therapy development (2009) Am. J. Obstet. Gynecol. 201:1-7. * Equal contributors
47. Nadav, L., Shay, T., Dezorella, N., Naparstek, E., Domany, E., Katz, B.-Z., and Geiger, B. Adhesive interactions regulate transcriptional diversity in malignant B-cells (2010) Mol. Cancer Res. 8:482-493.
48. Deutsch, V., Hubel, E., Kay, S., Ohayon, T., Katz, B.-Z., Many, A., Zander, A., Naparstek, E., and Grisaru, D. Mimicking the haematopoietic niche microenvironment provides a novel strategy for expansion of haematopoietic and megakaryocyte-progenitor cells from cord blood. (2010) Br. J. Hematol. 149:137-149.
49. Katz, B.-Z.  Adhesion molecules – the lifelines of multiple myeloma cells. (2010) Sem. Cancer Biol. 20:186-195.
50. Sarig, G., Garach-Jehoshua, O., Deutch, V., Winder, A., Hyam, E., Katz, B.-Z., Lahav, J., Cassel, A., Zivelin, A., Souroujon, M., Shimron, O.; Israeli Sub-Committee of Thrombosis and Hemostasis Laboratories. Laboratory evaluation of lupus anticoagulant in Israel. (2010) Harefuah 149:288-290, 336.

51. Deutsch, V., Katz, B.-Z., Tomer, A. Megakaryocyte development and platelet production in normal and disease states. (2010) Harefuah 2010 149:291-297, 336.

52. Tavor. S., Rothman, R., Golan, T., Voskoboinik, N., Katz, B.-Z., Sarid, N., Shomrat, R.,  Orr-Urtreger, Avi., Naparstek, E. The predictive value of TP53 FISH in cytogenetic subgroups of acute myeloid leukemia. (2011) Leukem. Lymphom. In press.

Book chapters:
1. Katz, B.-Z., Krylov, D., Vinson, C. and Yamada, K. M. A novel application for producing site-specific modifications of subcellular structures: enzymatic modulation of focal contacts by leucine zipper-mediated targeting. (2001) Cloning and Expression Vectors for Gene Function Analysis, Lu Q. and Weiner M. P. Eds, BioTechniques Press, 191-194.
Letters & Editorials:
1. Danckwardt, S., Hartmann, K., Katz, B., Ben-Tal, O. and Kulozik A. E. More on: Functional analysis of two prothrombin 3' UTR variants: the C20209T variant, mainly found among African-Americans, and the C20209A variant. (2006) J. Thromb. Hemost. 4:2288-2289.
2. Katz, B.-Z. and Polliack A. Discrepancies in quantitative assessment of bone marrow involvement in lymphoma: Do they reflect specialized micro-environmental cellular niches and cell-stromal interactions? (2006) Leukem. Lymphom. 47:1730-1731.
3. Katz B.-Z. Side populations – following the footprints of the elusive multiple myeloma stem cells ? (2008) Leukem. Lymphom. 49:1657-1658.
4. Katz B.-Z. and Tavor, S. The SDF-1\CXCR4 axis– a legitimate therapeutic target in Multiple Myeloma ? (2009) Leukem. Lymphom. 50:1067-1068.
5. Katz B.-Z. Adhesive interactions: the multi-task biochemical toolbox of cancer cells. (2010) Sem. Cancer Biol. 20:125-127.

1991 Gutwirth Fellowship, Tel-Aviv University, Tel-Aviv, Israel.

1991 Trotzky Fellowship, Tel-Aviv University, Tel-Aviv, Israel.

1992 International Cancer Research Technology Transfer (ICRETT) award,         the Lombardi Cancer Research Center, Georgetown University, Washington DC, USA.

1994-1998 Fogarty Post-Doctoral Fellowship, Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda MD, USA.

2001 CapCure research grant, Role of glycosaminoglycan-mediated adhesion in the regulation of prostate cancer development, Co-Principle Investigator ($50,000)

2002 CapCure research grant, Inhibition of prostate cancer metastasis: targeting the mechanism of prostate cell locomotion, Co-Principle Investigator ($50,000)

2002-2005 German Israel Fund research grant, The contribution of the heparan sulfate processing enzyme “heparanase” in vascular cell adhesive functions: Role in cellular trafficking during inflammation and tumor metastasis, Co-Principle Investigator (EURO 200,000)

2005-2007 Wolfson Foundation, Tumor Cell Diversity: implications for cancer prognosis and treatment, Co-Principle Investigator ($ 90,000)

2007     The collaborative research program Tel-Aviv Medical Center/Weizmann Institute of Science, Identification and therapeutic targeting of clinically significant sub-populations of Multiple Myeloma cells, Co-Principle Investigator ($ 40,000)

2008-2011   Israel Science Foundation, The regulatory mechanisms and function of CD38 in malignant plasma cell physiology, Principle Investigator (112,000 NIS/year)  

Israel Society for Clinical Laboratory Sciences, Israel (2001-present)

Israel Society for Hematology and Blood Transfusions, Israel (2001-present)
Board member – 12.2005-1.2008

Israel Society for Thrombosis and Hemostasis, Israel (2003-present)
Board member – 3.2011-present

The International Society of Tumor Microenvironment (2008-present)

Israel Society of Cancer Research (2009-present)

The European Association for Cancer Research (2010-present)